Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
8
|
| pubmed:dateCreated |
1991-9-12
|
| pubmed:abstractText |
Experimental ischemia models have shown the antitussive dextromethorphan to be an N-methyl-D-aspartate antagonist with neuroprotective properties. We treated 10 patients with a history of recent stroke or transient ischemic attack with oral dextromethorphan (60 mg q.i.d.) for 3 weeks in a placebo-controlled, double-blind, crossover tolerance study. We documented no clinical evidence of toxicity attributable to dextromethorphan in this preliminary study.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Aug
|
| pubmed:issn |
0039-2499
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
22
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1075-7
|
| pubmed:dateRevised |
2007-11-14
|
| pubmed:meshHeading |
pubmed-meshheading:1866755-Administration, Oral,
pubmed-meshheading:1866755-Aged,
pubmed-meshheading:1866755-Brain Ischemia,
pubmed-meshheading:1866755-Cerebrovascular Disorders,
pubmed-meshheading:1866755-Dextromethorphan,
pubmed-meshheading:1866755-Double-Blind Method,
pubmed-meshheading:1866755-Humans,
pubmed-meshheading:1866755-Ischemic Attack, Transient,
pubmed-meshheading:1866755-Middle Aged,
pubmed-meshheading:1866755-Risk Factors
|
| pubmed:year |
1991
|
| pubmed:articleTitle |
Safety and tolerance of oral dextromethorphan in patients at risk for brain ischemia.
|
| pubmed:affiliation |
Department of Neurology and Neurological Sciences, Stanford University Medical Center, Calif.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Randomized Controlled Trial
|